Patent application number | Description | Published |
20130069226 | SEMICONDUCTOR PACKAGE HAVING INTERPOSER - A semiconductor package includes a first structural body having a first surface and a second surface which faces away from the first surface, and formed with first connection members on the first surface; a second structural body placed over the first structural body, and formed with second connection members on a surface thereof which faces the first surface of the first structural body; and an interposer interposed between the first structural body and the second structural body, and having a body which is formed with openings into which the first connection members and the second connection members are inserted and a conductive layer which is formed to fill the openings. | 03-21-2013 |
20130089542 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject. | 04-11-2013 |
20130089557 | ANTIBODY SPECIFICALLY BINDING TO EPITOPE IN SEMA DOMAIN OF C-MET - An antibody or antigen binding fragment thereof that specifically binds to an epitope in a SEMA domain of c-Met protein, and pharmaceutical compositions, methods, kits, nucleic acids, and cells related thereto. | 04-11-2013 |
20130094686 | PORTABLE TERMINAL - A portable terminal is provided. The portable terminal includes a display panel, a case member provided to surround at least both sides of the display panel, and a speaker hole formed in the case member and opened to at least one side of the display panel. The portable terminal includes the speaker hole in at least a side of the display panel by changing only a structure of the case member, such that the volume and quality of sound output from the speaker device can be fully delivered to a user who uses the terminal while viewing the display panel. | 04-18-2013 |
20130129731 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti c-Met antibody or antigen-binding fragment thereof comprising a heavy-chain variable region having heavy-chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOs: 1, 2 and 3, and a light-chain variable region having light-chain CDR amino acid sequences of SEQ ID NOs: 4, 5, and 6; and a method of wound healing, tissue regeneration, or cell proliferation comprising administration of same; as well as related compositions and methods. | 05-23-2013 |
20130164281 | DEIMMUNIZED ANTI C-MET HUMANIZED ANTIBODIES AND USES THEREOF - A deimmunized anti c-Met humanized antibody and a pharmaceutical composition including the same, and method for the prevention and treatment of cancer. | 06-27-2013 |
20140134645 | METHOD OF ISOLATING OR COUNTING TARGET CELLS BY USING PHOTOCLEAVABLE LINKER COUPLED WITH FLUORESCENT DYE - A method of isolating or counting target cells using photocleavable linkers coupled with fluorescent dyes, for qualitative or quantitative analysis of protein, gene analysis, and/or morphological analysis after removing the dye. | 05-15-2014 |
20140154251 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided. | 06-05-2014 |
20140294814 | HUMANIZED AND AFFINITY-MATURED ANTI-C-MET ANTIBODY AND USES THEREOF - Provided is a humanized and affinity-matured anti-c-Met antibody, a pharmaceutical composition including the antibody, and a method of preventing and/or treating c-Met-related disease using the antibody. | 10-02-2014 |
20140294837 | FUSION PROTEIN COMPRISING ANTI-C-MET ANTIBODY AND VEGF-BINDING FRAGMENT - There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment. | 10-02-2014 |
20140294838 | BISPECIFIC ANTI-CMET/ANTI-HER2 ANTIBODIES - There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same. | 10-02-2014 |
20140302029 | ANTI-C-MET/ANTI-EGFR BISPECIFIC ANTIBODIES - There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for preventing and/or treating cancer using the same, and an anti-EGFR scFv fragment. | 10-09-2014 |
20140356366 | COMPOSITION FOR TARGET MEMBRANE PROTEIN DEPLETION - A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions. | 12-04-2014 |
20150030596 | BISPECIFIC CHIMERIC PROTEINS WITH DARPins - A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions. | 01-29-2015 |
20150030599 | ANTI-EGFR ANTIBODY AND ANTI-C-MET/ANTI-EGFR BISPECIFIC ANTIBODIES COMPRISING THE SAME - An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided. | 01-29-2015 |